Olympus has announced the full market release of its AI-powered SeleCT™ Screening program for emphysema, leveraging 4DMedical’s technology to automatically review existing chest CT scans and identify patients who may benefit from bronchoscopic lung volume reduction (BLVR) using the Spiration™ Valve System. This initiative highlights the commercial integration and broad deployment of 4DMedical’s AI in a major U.S. healthcare ecosystem, supporting early diagnosis and targeted intervention for the millions affected by emphysema and COPD. The SeleCT Screening tool is poised to enhance clinical outcomes by expediting the identification and treatment of suitable patients.